GlassScriptPhysician profile
Karaneh Karimi
NPI 1295296051
$5,642.72
in general payments reported to CMS, 2019-2025
23 companies · $3,005 in 2025
The $3,005 reported for 2025 was more than what 84% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $520 · 2024: $2,117 · 2025: $3,005.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,342 · Education: $297 · Travel and Lodging: $3.85.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,342.02 |
| Education | $296.85 |
| Travel and Lodging | $3.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $988.16 | 2023-2025 | Tremfya, Stelara, Simponi Aria |
| Galderma Laboratories, L.P. | $965.96 | 2023-2025 | Nemluvio, Aklief |
| Arcutis Biotherapeutics, INC. | $629.68 | 2024-2025 | Zoryve |
| Abbvie INC. | $415.35 | 2024-2025 | |
| Sun Pharmaceutical Industries INC. | $407.09 | 2024-2025 | |
| Regeneron Healthcare Solutions, INC. | $337.74 | 2023-2025 | Dupixent, Libtayo |
| Organon LLC | $304.08 | 2025 | Vtama |
| Lilly USA, LLC | $253.98 | 2023-2025 | Olumiant, Taltz, Ebglyss |
| E.R. Squibb & Sons, L.L.C. | $221.01 | 2024-2025 | Sotyktu |
| Incyte Corporation | $209.39 | 2023-2025 | Opzelura |
| Pfizer INC. | $169.34 | 2024-2025 | |
| Ucb, INC. | $167.64 | 2023-2025 | Bimzelx |
| Amgen INC. | $162.07 | 2024-2025 | Otezla, Otezla |
| Bolton Medical INC | $109.57 | 2024 | Treo Abdominal Stent-Graft System |
| Biofrontera INC. | $78.30 | 2023-2024 | Ameluz, Xepi, Bf-Rhodoled |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Leo Pharma INC. | $52.81 | 2025 | Adbry |
| Medimetriks Pharmaceuticals, INC. | $35.96 | 2024-2025 | Neo-Synalar |
| Genzyme Corporation | $28.84 | 2025 | |
| Dermavant Sciences, INC. | $28.45 | 2024 | Vtama |
| Novartis Pharmaceuticals Corporation | $23.89 | 2023 | |
| Botanix Sb INC | $18.74 | 2025 | Sofdra |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $17.84 | 2024 | Siliq |
| Cipher Pharmaceuticals US LLC | $16.83 | 2025 | Spinosad, Natroba |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Karaneh Karimi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.